Rezolute(US:RZLT) Businesswire·2025-12-11 19:30Core Insights - Rezolute, Inc. is facing potential legal claims following a significant drop in its stock price due to disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3] Group 1: Company Performance - On December 11, 2025, Rezolute, Inc. shares fell sharply, with a decline from approximately $10.94 to an intraday low of around $0.90, representing an approximate 85-90% drop [2][3] - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [2] Group 2: Legal Investigation - Faruqil & Faruqil, LLP is investigating potential claims against Rezolute, indicating that the firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [1]